LivaNova PLC (NASDAQ:LIVN) Shares Purchased by LSV Asset Management

Key Points

• LSV Asset Management significantly increased its holdings in LivaNova PLC by 278.3%, owning 438,498 shares valued at approximately $17.22 million.
• Analysts have set a consensus price target for LivaNova at $59.29, with several institutions boosting their ratings, including Robert W. Baird raising it to $61.00.
• LivaNova shares traded down 0.4%, reaching $42.61, with a market capitalization of approximately $2.32 billion.

LSV Asset Management raised its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 278.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 438,498 shares of the company's stock after purchasing an additional 322,598 shares during the quarter. LSV Asset Management owned 0.80% of LivaNova worth $17,224,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Seizert Capital Partners LLC purchased a new stake in shares of LivaNova in the first quarter valued at approximately $3,896,000. Bayforest Capital Ltd purchased a new stake in shares of LivaNova in the first quarter valued at approximately $590,000. XTX Topco Ltd purchased a new stake in shares of LivaNova in the first quarter valued at approximately $557,000. GSA Capital Partners LLP boosted its stake in shares of LivaNova by 313.3% in the first quarter. GSA Capital Partners LLP now owns 32,298 shares of the company's stock valued at $1,269,000 after buying an additional 24,483 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of LivaNova by 0.9% in the first quarter. Federated Hermes Inc. now owns 144,116 shares of the company's stock valued at $5,661,000 after buying an additional 1,223 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LIVN has been the topic of a number of analyst reports. Barclays decreased their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Finally, Robert W. Baird lifted their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $59.29.

LivaNova Price Performance

LIVN stock traded up $1.35 during midday trading on Friday, hitting $49.87. 397,809 shares of the stock were exchanged, compared to its average volume of 706,882. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -12.82 and a beta of 0.92. The stock's 50-day moving average price is $44.72 and its 200-day moving average price is $42.82. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The company had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. During the same period in the previous year, the firm posted $0.93 earnings per share. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. Research analysts predict that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.